Last reviewed · How we verify
Trilaciclib, carboplatin, etoposide，or Topotecan
Trilaciclib, carboplatin, etoposide，or Topotecan is a CDK4/6 inhibitor Small molecule drug developed by Jiangsu Simcere Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Small cell lung cancer, Extensive-stage small cell lung cancer. Also known as: Trilaciclib plus chemotherapy.
Trilaciclib is a CDK4/6 inhibitor that blocks cell cycle progression.
Trilaciclib is a CDK4/6 inhibitor that blocks cell cycle progression. Used for Small cell lung cancer, Extensive-stage small cell lung cancer.
At a glance
| Generic name | Trilaciclib, carboplatin, etoposide，or Topotecan |
|---|---|
| Also known as | Trilaciclib plus chemotherapy |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | CDK4/6 inhibitor |
| Target | CDK4/6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trilaciclib works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for cell cycle progression. By blocking these kinases, trilaciclib prevents cancer cells from dividing and growing. This mechanism is particularly effective in combination with chemotherapy agents like carboplatin and etoposide.
Approved indications
- Small cell lung cancer
- Extensive-stage small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
- Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients (PHASE3)
- Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study (PHASE4)
- Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trilaciclib, carboplatin, etoposide，or Topotecan CI brief — competitive landscape report
- Trilaciclib, carboplatin, etoposide，or Topotecan updates RSS · CI watch RSS
- Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Trilaciclib, carboplatin, etoposide，or Topotecan
What is Trilaciclib, carboplatin, etoposide，or Topotecan?
How does Trilaciclib, carboplatin, etoposide，or Topotecan work?
What is Trilaciclib, carboplatin, etoposide，or Topotecan used for?
Who makes Trilaciclib, carboplatin, etoposide，or Topotecan?
Is Trilaciclib, carboplatin, etoposide，or Topotecan also known as anything else?
What drug class is Trilaciclib, carboplatin, etoposide，or Topotecan in?
What development phase is Trilaciclib, carboplatin, etoposide，or Topotecan in?
What are the side effects of Trilaciclib, carboplatin, etoposide，or Topotecan?
What does Trilaciclib, carboplatin, etoposide，or Topotecan target?
Related
- Drug class: All CDK4/6 inhibitor drugs
- Target: All drugs targeting CDK4/6
- Manufacturer: Jiangsu Simcere Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Extensive-stage small cell lung cancer
- Also known as: Trilaciclib plus chemotherapy
- Compare: Trilaciclib, carboplatin, etoposide，or Topotecan vs similar drugs
- Pricing: Trilaciclib, carboplatin, etoposide，or Topotecan cost, discount & access